4 ms·
Merck can't benefit from both ivermectin & their new emergency-use-authorized drug. Emergency use authorization requires "no adequate, approved, and available a
by eruleman 5y ago
Merck can't benefit from both ivermectin & their new emergency-use-authorized drug. Emergency use authorization requires "no adequate, approved, and available alternatives." [1]
It's against their financial incentive to have ivermectin, an out-of-patent drug, be authorized for treatment of covid. See https://twitter.com/BretWeinstein/status/1402647948371005441?s=20 https://twitter.com/BretWeinstein/status/1402647948371005441...
[1] https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained https://www.fda.gov/vaccines-blood-biologics/vaccines/emerge...
- Pyramus 5y agoI don't get it. So are you saying somebody else should go for EUA for ivermectin for Covid, and then Merck couldn't go for EUA for their new drug? Or are you saying Merck couldn't go for several EUAs for Covid at the same time?
- briefcomment 5y agoMerck can't get an EUA for their new drug if there's an existing treatment that works. If Ivermectin works, then their other drug becomes worthless. Same thing for the mRNA vaccines. They're all under EUA. It would've been impossible to get them an EUA if we had found out Ivermectin worked.